

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia https://doi.org/10.1007/s00125-018-4772-2.

Manuscript DOI: https://doi.org/10.2337/ DB20-0616

Title: Non-invasive monitoring of glycemia-induced regulation of GLP-1R expression in murine and human islets of Langerhans
Author list: M.Buitinga, C.M.Cohrs, W.A.Eter, L.Claessens-Joosten, C.Frielink, D.Bos, G. Sandker, M.Brom, S.Speier, M.Gotthardt

Corresponding author: Mijke Buitinga

Email address: mijkebuitinga@hotmail.com

Islet preparation	1	2	3	4	5	6	7	8 ª
MANDATORY INFORMATION								
Unique identifier	Lot HP- 17075-01							
Donor age (years)	37							
Donor sex (M/F)	F							
Donor BMI (kg/m²)	19.57							

Donor HbA _{1c} or other measure of blood glucose control	4.6%							
Origin/source of islets ^b	Prodo Laboratories							
Islet isolation centre	Prodo Laboratories							
Donor history of diabetes? Yes/No	No							
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

RECOMMENDED INFORMATION								
Donor cause of death	anoxic event							
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)	90				
Estimated viability (%)	90				
Total culture time (h)d	o.n. after receiving				
Glucose-stimulated insulin secretion or other functional measuremente					
Handpicked to purity? Yes/No	Yes				
Additional notes					

^aIf you have used more than eight islet preparations, please complete additional forms as necessary ^bFor example, IIDP, ECIT, Alberta IsletCore ^cPlease specify the therapy/therapies ^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results